Clinical trials: Bronchogenic Cancer
Non-small Cell Lung Cancer
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
- Trial name
- NCT04324164
- Testing
- Third-generation EGFR-TKI, EGFR-TKI
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hunan Province Tumor Hospital
Lung Cancer Non-small Cell Stage IV
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
The purpose of this study is to investigate how well the standard treatment (platinum-based doublet chemotherapy) in combination with denosumab works compared with the standard treatment alone in patients with a type of lung…
- Trial name
- SPLENDOUR (NCT02129699)
- Testing
- Denosumab, None, standard chemotherapy only
- Where
- 66 sites in Austria, Belgium and 9 more
- Volunteers
- 595 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non-small Cell Lung Cancer
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with…
- Trial name
- NCT06382116
- Testing
- BL-B01D1, Pemetrexed+Cisplatin or Carboplatin
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate YL202 monotherapy versus Docetaxel in participants with locally…
- Trial name
- NCT07416994
- Testing
- YL202, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Metastatic Non-small Cell Lung Cancer
PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic non-small cell lung cancer. Blood samples will also be collected for research purposes.
- Trial name
- NCT02793856
- Testing
- Cyclophosphamide, PD-1 Knockout T Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Lung Neoplasms, Non-Small Cell Lung Cancer
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer
Osimertinib is a standard first-line treatment for patients with metastatic non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 deletion or exon 21 L858R mutation.
- Trial name
- PTR-2 (NCT07738172)
- Testing
- Primary Tumor Resection, Osimertinib
- Where
- Taiwan
- Volunteers
- 154 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer, Non-small Cell
Neoadjuvant Immunotherapy in Advanced NSCLC
A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC.
- Trial name
- NCT05137912
- Testing
- Immunotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Power Life Sciences Inc.
Lung Cancer, Lung Adenocarcinoma
Identify Prognostic Biomarkers of Lung Cancer
Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.
- Conditions
- Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT05010330
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Bladder Cancer, Breast Cancer
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00471432
- Testing
- custirsen sodium, docetaxel, pharmacological study
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Stage II-III Non-small Cell Lung Cancer
Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection
Neoadjuvant chemo-immunotherapy, with or without adjuvant immunotherapy, is currently the standard of care for resectable stage II-III NSCLC.
- Trial name
- NoSurgery (NCT07131163)
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Breast Cancer, Colorectal Cancer
Family Quality of Life Among Families With a Member Who is a Cancer Patient
RATIONALE: Developing a questionnaire that can be used to assess the quality of life among people who have a family member with cancer may help the study of cancer in the future.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00544336
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer
Feasibility of re Biopsies at Progression
Feasibility of new biological and histological samples at progression in patients with advanced or metastatic Non Small Cell Lung Cancer (NSCLC). A recent paper from Professor Sequist and coll.
- Trial name
- GFPC-REBIOP (NCT02086071)
- Testing
- re biopsy
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer
platinum-based albumin-bound paclitaxel regimen in advanced non-small cell lung cancer (NSCLC) especially in lung squamous cell carcinoma has a better tumor response rate and safety than solvent-based paclitaxel.However, the…
- Trial name
- NCT02016209
- Testing
- nanoparticle albumin-bound paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer
Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）
This is a randomized, controlled, phase II/III clinical study to evaluate the efficacy and safety of stand-of-care systemic therapy with local therapy versus stand-of-care systemic therapy in patients with oligoprogressive…
- Trial name
- NCT07076693
- Testing
- Radiotherapy or Surgery, Standard Medical Therapy
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Shanghai Chest Hospital
Non-small-cell Lung Cancer
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
This is an open-label, multicenter, randomized, phase II clinical trial, which aims to evaluate the effectiveness and safety of gefitinib versus combination of gefitinib and doublet chemotherapy or apatinib in advanced non-small…
- Trial name
- NCT03267654
- Testing
- gefitinib combined with chemotherapy, gefitinib combined with apatinib, gefitinib single agent
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
Background: Drugs known as poly-adenosine diphosphate ribose polymerase (PARP) inhibitors are known to help stop tumor growth in patients with breast, ovarian cancers and many other cancers including prostate and pancreatic…
- Trial name
- NCT04209595
- Testing
- PLX038, Rucaparib, Ondansetron
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00560495
- Testing
- ammonium tetrathiomolybdate, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Small Cell Lung Cancer
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
Lung cancer is one of the malignant tumors with the highest incidence and mortality rates globally, with small cell lung cancer (SCLC) accounting for approximately 15%.
- Trial name
- NCT07026669
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with relapsed or…
- Trial name
- NCT00003666
- Testing
- 6-hydroxymethylacylfulvene
- Where
- 48 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer, Small Cell Lung Carcinoma
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
- Trial name
- NCT05265429
- Testing
- Data and Specimen Collection
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.